MIN 102

Drug Profile

MIN 102

Alternative Names: MIN-102

Latest Information Update: 23 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IDIBELL
  • Developer Minoryx Therapeutics
  • Class Small molecules; Thiazolidinediones
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy
  • New Molecular Entity No

Highest Development Phases

  • Phase I Adrenoleucodystrophy

Most Recent Events

  • 21 Mar 2017 Adverse events data from a phase I trial in Adrenoleukodystrophy released by Minoryx Therapeutics
  • 21 Mar 2017 Minoryx Therapeutics completes a phase I trial in Adrenoleukodystrophy (In volunteers) in Spain (PO)
  • 22 Feb 2017 MIN 102 receives Orphan Drug status for Adrenoleucodystrophy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top